These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 30132336)

  • 21. Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention.
    Sawlani NN; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL
    Circ Cardiovasc Interv; 2017 Jan; 10(1):. PubMed ID: 28039321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Tolerability of Transitioning from Cangrelor to Ticagrelor in Patients Who Underwent Percutaneous Coronary Intervention.
    Badreldin HA; Carter D; Cook BM; Qamar A; Vaduganathan M; Bhatt DL
    Am J Cardiol; 2017 Aug; 120(3):359-361. PubMed ID: 28576266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
    Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial.
    Stone GW; Généreux P; Harrington RA; White HD; Gibson CM; Steg PG; Hamm CW; Mahaffey KW; Price MJ; Prats J; Deliargyris EN; Bhatt DL
    Eur Heart J; 2018 Dec; 39(46):4112-4121. PubMed ID: 30203006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Safety Evaluation of Cangrelor in Patients Undergoing PCI.
    Franchi F; Rollini F; Park Y; Angiolillo DJ
    Expert Opin Drug Saf; 2016; 15(2):275-85. PubMed ID: 26680584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel use of cangrelor in pediatrics: A pilot cohort study demonstrating use in ventricular assist devices.
    Fahnhorst SE; Beasley G; Goldberg JF; Martinez HR; Ryan KA; Towbin JA; Boston U; Absi M
    Artif Organs; 2021 Jan; 45(1):38-45. PubMed ID: 33180355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention: Results From the European PREvention of Stent Thrombosis by an Interdisciplinary Global European Effort Registry.
    Godschalk TC; Byrne RA; Adriaenssens T; Malik N; Feldman LJ; Guagliumi G; Alfonso F; Neumann FJ; Trenk D; Joner M; Schulz C; Steg PG; Goodall AH; Wojdyla R; Dudek D; Wykrzykowska JJ; Hlinomaz O; Zaman AG; Curzen N; Dens J; Sinnaeve P; Desmet W; Gershlick AH; Kastrati A; Massberg S; Ten Berg JM;
    JACC Cardiovasc Interv; 2017 Dec; 10(24):2548-2556. PubMed ID: 29268884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cangrelor for treatment of arterial thrombosis.
    Walsh JA; Price MJ
    Expert Opin Pharmacother; 2014 Mar; 15(4):565-72. PubMed ID: 24479981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of cangrelor in acute stenting for the treatment of cerebrovascular pathology: preliminary experience in a single-center pilot study.
    Aguilar-Salinas P; Agnoletto GJ; Brasiliense LBC; Santos R; Granja MF; Gonsales D; Aghaebrahim A; Sauvageau E; Hanel RA
    J Neurointerv Surg; 2019 Apr; 11(4):347-351. PubMed ID: 30552167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cangrelor for treatment during percutaneous coronary intervention.
    Oestreich JH; Dobesh PP
    Future Cardiol; 2014 Mar; 10(2):201-13. PubMed ID: 24762247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiplatelet therapy. Cangrelor succeeds, at last, in PCI.
    Storey RF
    Nat Rev Cardiol; 2013 Jun; 10(6):302-4. PubMed ID: 23609175
    [No Abstract]   [Full Text] [Related]  

  • 32. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).
    Cavender MA; Bhatt DL; Stone GW; White HD; Steg PG; Gibson CM; Hamm CW; Price MJ; Leonardi S; Prats J; Deliargyris EN; Mahaffey KW; Harrington RA;
    Circulation; 2016 Sep; 134(10):723-33. PubMed ID: 27482008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Feasibility and safety of cangrelor in patients with suboptimal P2Y
    Selvarajah A; Tavenier AH; Bor WL; Houben V; Rasoul S; Kaplan E; Teeuwen K; Hofma SH; Lipsic E; Amoroso G; van Leeuwen MAH; Berg JMT; van 't Hof AWJ; Hermanides RS
    BMC Cardiovasc Disord; 2021 Jun; 21(1):292. PubMed ID: 34118880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.
    Cavender MA; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Lopes RD; Leonardi S; Deliargyris EN; Prats J; Mahaffey KW; White HD; Bhatt DL;
    Circ Cardiovasc Interv; 2022 Jan; 15(1):e010390. PubMed ID: 34915723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of Cangrelor Use After Percutaneous Coronary Intervention in Patients With Mechanical Circulatory Support.
    Pluenneke JC; Mohamed AM; Hayes CH; Berry TP; Thomas EL; Zhurav L; Kozinn JB; Haines MM; Welge JA
    J Cardiothorac Vasc Anesth; 2023 Dec; 37(12):2511-2516. PubMed ID: 37775345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What Are Optimal P2Y12 Inhibitor and Schedule of Administration in Patients With Acute Coronary Syndrome?
    Cohen MV; Downey JM
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):121-130. PubMed ID: 31645108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial.
    Vaduganathan M; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL
    Circ Cardiovasc Interv; 2016 Jun; 9(6):e003612. PubMed ID: 27313282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.
    Angiolillo DJ; Firstenberg MS; Price MJ; Tummala PE; Hutyra M; Welsby IJ; Voeltz MD; Chandna H; Ramaiah C; Brtko M; Cannon L; Dyke C; Liu T; Montalescot G; Manoukian SV; Prats J; Topol EJ;
    JAMA; 2012 Jan; 307(3):265-74. PubMed ID: 22253393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.
    Angiolillo DJ; Schneider DJ; Bhatt DL; French WJ; Price MJ; Saucedo JF; Shaburishvili T; Huber K; Prats J; Liu T; Harrington RA; Becker RC
    J Thromb Thrombolysis; 2012 Jul; 34(1):44-55. PubMed ID: 22569899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.